Purpose:To observe the short-term efficacy of thoracic endovascular aortic repair (TEVAR) using a single left common carotid artery chimney stent combined with a Castor single-branched stent-graft (SC-TEVAR) in the treatment of zone 2 (Z2) aortic diseases.Materials and Methods:To conduct a retrospective analysis of 20 patients with Z2 aortic diseases who were treated in our department from June 2021 to April 2022. The lesions included true aortic degenerative aneurysms with diameter ≥5.0 cm and penetrating aortic ulcers with depth >1.0 cm or basal width >2.0 cm. All 20 patients accepted the SC-TEVAR treatment, which was a new hybrid method to assure the flow of the left common carotid artery (LCCA) and left subclavian artery (LSA). This method was defined as a concomitant chimney stent for LCCA and a Castor single-branched stent graft for the aorta and LSA. The baseline data and intraoperative data were collected to evaluate the safety and efficacy of this method. The patency of the target blood vessel and any associated complications were evaluated at 1 and 6 months postoperatively, to analyze the safety and efficacy of this new method.Results:After discharge from the hospital, all patients were followed up by a specific follow-up team. At 6 monthly follow-up period, there were no cardiac events, stroke, hemiplegia, type I endoleak, type II endoleak, proximal stent graft-induced new entries, distal stent graft-induced new entries, wound infection, or bleeding. Only 1 patient developed an inguinal wound hematoma and got conservative treatment. Importantly, no patients developed stenosis or occlusion of the LCCA or LSA. The patency of branched arteries was 100%. The technical success rate was 90%.Conclusion:SC-TEVAR appears to be a new and relatively simple, safe, and effective treatment for Z2 aortic diseases.Clinical ImpactThis was a single-center retrospective cohort study. A total of 20 patients with zone 2 aortic diseases accepted a new hybrid surgical method named SC-TEVAR. This method was not complicated and could be finished with only 3 peripheral artery exposure. The result showed no mortality, 100% patency of the branch artery, and 90% of technical success in 6 months of follow-up time. SC-TEVAR showed a satisfactory result in this retrospective study and could be promoted as an easy method to treat zone 2 aortic diseases.

中文翻译：

---

单支左颈总动脉支架联合Castor单支覆膜血管腔内修复治疗主动脉2区局部疾病的疗效

目的：观察左颈总动脉烟囱状支架联合Castor单分支覆膜支架（SC-TEVAR）进行胸主动脉腔内修复术（TEVAR）治疗2区（Z2）的近期疗效。材料与方法：对2021年6月至2022年4月在我科收治的20例Z2型主动脉疾病患者进行回顾性分析，病变包括直径≥5.0 cm的真性主动脉退行性动脉瘤和深度主动脉穿透性溃疡>1.0 厘米或底宽 >2.0 厘米。所有20名患者均接受了SC-TEVAR治疗，这是一种新的混合方法，可确保左颈总动脉（LCCA）和左锁骨下动脉（LSA）的血流。该方法被定义为用于 LCCA 的伴随烟囱支架和用于主动脉和 LSA 的 Castor 单分支支架移植物。收集基线数据和术中数据来评估该方法的安全性和有效性。术后1个月和6个月评估目标血管的通畅情况以及任何相关并发症，以分析这种新方法的安全性和有效性。结果：出院后，所有患者均进行了具体随访团队。随访6个月时，无心脏事件、中风、偏瘫、I型内漏、II型内漏、近端覆膜支架引起的新入口、远端覆膜支架引起的新入口、伤口感染或出血。仅1例患者出现腹股沟伤口血肿并接受保守治疗。重要的是，没有患者出现 LCCA 或 LSA 狭窄或闭塞。分支动脉通畅率为100%。技术成功率为90%。结论：SC-TEVAR似乎是一种新的、相对简单、安全、有效的Z2主动脉疾病治疗方法。临床影响这是一项单中心回顾性队列研究。共有 20 名患有 2 区主动脉疾病的患者接受了名为 SC-TEVAR 的新型混合手术方法。该方法并不复杂，只需暴露3条外周动脉即可完成。结果显示，在 6 个月的随访时间内，没有死亡，分支动脉 100% 通畅，技术成功率为 90%。SC-TEVAR 在这项回顾性研究中显示出令人满意的结果，可以作为治疗 2 区主动脉疾病的简便方法进行推广。